article thumbnail

Chinese tech giant Baidu licenses mRNA algorithm to Sanofi

pharmaphorum

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs.

Licensing 105
article thumbnail

AbbVie preps filings for lymphoma bispecific licensed from Genmab

pharmaphorum

billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead drug in the partnership – epcoritamab for large B-cell lymphoma (LBCL). The post AbbVie preps filings for lymphoma bispecific licensed from Genmab appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clinical trial will test novel inhaled TB vaccine

Drug Discovery World

The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. This important new study will help us to see whether giving BCG more than once stimulates a stronger immune response and whether giving it by inhalation is better than giving it into the skin.

article thumbnail

New class of antibody cancer drug shows promise

Drug Discovery World

The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether an IgE antibody could be used to treat cancer. The drug, MOv18 IgE, was developed by researchers at King’s College London. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

article thumbnail

Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal

pharmaphorum

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. It was shown to activate cell-killing immune responses via natural killer (NK) and CD8+ cells, as well as antigen-presenting cells.

Drugs 105
article thumbnail

Ginkgo Bioworks to discover and develop novel vaccine adjuvants 

Drug Discovery World

Licensing for human use Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination. The post Ginkgo Bioworks to discover and develop novel vaccine adjuvants appeared first on Drug Discovery World (DDW).

article thumbnail

2023 cancer research highlights: Drug development at its best

Drug Discovery World

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.